GlassScriptPhysician profile
Saloni Sharma Paudel
NPI 1205181302
$1,455.23
in general payments reported to CMS, 2019-2025
31 companies · $348 in 2025
The $348 reported for 2025 was more than what 88% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $141 · 2020: $111 · 2021: $225 · 2022: $71.36 · 2023: $344 · 2024: $216 · 2025: $348.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $908.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $907.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $136.55 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $122.68 | 2020-2021 | |
| Tris Pharma INC | $117.40 | 2019-2025 | Dyanavel Xr, Onyda Xr |
| Cranial Technologies, INC | $113.66 | 2021-2025 | Doc Band |
| Supernus Pharmaceuticals, INC. | $113.11 | 2023-2025 | Qelbree, Qelbree |
| Pfizer INC. | $99.95 | 2019-2025 | |
| Corium, LLC | $87.75 | 2022-2023 | Azstarys |
| Adlon Therapeutics L.P. | $60.64 | 2020-2021 | |
| Dexcom, INC. | $57.08 | 2024-2025 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $47.92 | 2020-2025 | |
| Lilly USA, LLC | $47.20 | 2020-2022 | |
| Nevro Corp. | $45.27 | 2023 | Senza |
| Ironshore Pharmaceuticals INC. | $40.05 | 2019-2023 | Jornay Pm |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $39.74 | 2021-2024 | Xifaxan |
| Glaxosmithkline, LLC. | $38.07 | 2019-2023 | Pediarix, Bexsero |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $35.96 | 2019-2023 | Evenity, Prolia |
| Abiomed | $30.84 | 2025 | |
| Shield Therapeutics INC | $30.54 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.62 | 2025 | Caplyta |
| Nestle Healthcare Nutrition INC. | $16.73 | 2023 | |
| Ascensia Diabetes Care US INC. | $16.72 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $16.15 | 2025 | Farxiga |
| Sanofi-Aventis U.S. LLC | $15.81 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $14.85 | 2024 | Eliquis |
| Philips North America LLC | $14.33 | 2022 | |
| Sanofi Pasteur INC. | $13.94 | 2019 | |
| Sobi, INC | $13.72 | 2021 | |
| Genentech USA, INC. | $13.62 | 2019 | |
| Vistapharm, INC. | $12.99 | 2021 | |
| Merck Sharp & Dohme LLC | $11.69 | 2019 | |
| Phathom Pharmaceuticals, INC. | $11.65 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saloni Paudel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.